Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hospira recall

This article was originally published in The Gray Sheet

Executive Summary

Firm says models of its Symbiq one-channel and two-channel infusion pumps may fail to detect air in the line at the end of an infusion. Delivering air to patients could result in serious injury or death, Hospira notes. FDA classified the recall as Class I, the most serious category, on July 15. Hospira first alerted customers to the problem in April, and gave updated recommendations on June 11. Among them, users should not use polyethylene-lined microbore segment administration sets if other sets are available and should not run solution/medication containers dry; and they should enable the "nearing end of infusion" alarm on the devices or use an "air eliminating filter," if appropriate, the firm recommends. Symbiq pumps can still be used while a permanent fix is identified. Hospira had halted shipments in April to investigate customer complaints (1"The Gray Sheet" May 10, 2010)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel